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The in vitro biocompatibility performance of a 25 mmol/L bicar-
bonate/10 mmol/L lactate-buffered peritoneal dialysis fluid.
Background. The biocompatibility profile of a new peritoneal
dialysis (PD) solution (Physioneal 35) was determined using a
selection of in vitro assay systems. Physioneal 35 is buffered by a
combination of 25 mmol/L bicarbonate and 10 mmol/L lactate,
thereby providing a solution with a total of 35 mmol/L of alkali
to complement the currently available 25 mmol/L bicarbonate
and 15 mmol/L lactate combination solution, Physioneal 40. In
addition, the new solution contains a calcium concentration of
1.75 mmol/L rather than 1.25 mmol/L present in Physioneal 40.
Physioneal 35 and 40 are manufactured in double chamber bag
systems that permit separation of glucose from the buffer dur-
ing sterilization. When the two chambers are mixed just before
patient use, the resulting solution has a neutral pH and reduced
glucose degradation content. Physioneal 35 was evaluated for its
cytotoxicity potential using a murine fibroblast assay, its acute
effect on human neutrophil and human peritoneal mesothe-
lial cell function, and its in vitro potential to form advanced
glycation end products (AGE). The biocompatibility charac-
teristics of this new formulation were compared with that of
a conventional, lactate-based solution and to that of its parent
formulation, Physioneal 40.
Methods. Proliferation of murine fibroblasts was determined
after exposure to dialysis fluids for 72 hours. Cell viability was
assayed by the ability to take up neutral red dye. Human neu-
trophils were exposed for 15 minutes to dialysis fluids, and
their ATP content and phorbol 12-myristate 13-acetate (PMA)
stimulated chemiluminescence response was determined as a
measure of viability and respiratory burst activity, respectively.
Cellular interleukin (IL)-1b–driven IL-8 synthesis by human
mesothelial cells following acute exposure to dialysis fluids was
also assessed. Advanced glycation end product formation in the
dialysis fluids was measured after 5 and 20 days of incubation
with human serum albumin (HSA) as the model protein.
Results. In all assays employed, the biocompatibility profile
of Physioneal 35 was similar to that of the Physioneal 40 parent
formulation. Physioneal 35 showed a significant improvement
in biocompatibility performance compared to a pH neutral-
ized conventional lactate-buffered peritoneal dialysis solution
in the murine fibroblast assay. In the acute exposure assays,
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human neutrophil viability and respiratory burst were signif-
icantly improved compared with the acidic, conventional so-
lution; however, no statistically significant improvement were
seen in mesothelial cells. AGE formation, which is thought to be
an important mechanism by which glucose and glucose degra-
dation products cause structural and functional changes of the
peritoneal membrane, was significantly lower in Physioneal 35
compared with the conventional dialysis solution.
Conclusion. The biocompatibility profile of Physioneal 35
was similar to that of the original Physioneal 40 bicarbonate/
lactate-buffered dialysis solution, confirming that differences
in both buffer content and calcium concentration do not affect
biocompatibility performance. Both bicarbonate/lactate formu-
lations (Physioneal 35 and Physioneal 40) were more biocom-
patible than a conventional lactate-buffered dialysis solution in
this in vitro biocompatibility assessment.
The long-term success of chronic peritoneal dialysis
(PD) depends on the structural and functional mainte-
nance of the peritoneal membrane. Williams et al [1] have
reported that the peritoneal membrane undergoes slow
but progressive fibrosis and vasculopathy after the first
one to two years of continuous dialysis. Conventional PD
solutions have been suggested as one potential cause of
such changes [2]. Conventional dialysis solutions have a
low pH, high lactate content, hyperosmolar glucose con-
centrations, and levels of glucose degradation products
that are believed to be bioincompatible [3].
In order to improve the biocompatibility profile of
conventional PD solutions, adjustments are necessary to
achieve a more physiologic pH and buffer composition,
and reduce levels of glucose degradation products, espe-
cially those that are identified as biologically undesirable.
New formulations, such as Physioneal 40, have been de-
veloped to meet this clinical need. This new solution, now
commercially available in several regions of the world, is
manufactured in a double chamber bag system that per-
mits separation of glucose from a bicarbonate buffer dur-
ing sterilization. When the two chambers are mixed just
before patient use, the resulting solution has a neutral pH
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and reduced glucose degradation content. Physioneal 40
contains a physiologic level of bicarbonate (25 mmol/L)
combined with a reduced level of lactate (15 mmol/L)
compared to conventional PD solutions (typically 35–
40 mmol/L lactate). In clinical trials, Physioneal 40 was
found to cause less pain on infusion [4] than conventional
acidic dialysis solutions. Preclinical in vitro, ex vivo hu-
man, and in vivo animal studies have demonstrated that
this solution is more biocompatible than its acidic lactate–
buffered counterpart [5–8].
To allow for adequate clinical management of acid-
base and calcium balance, a second formulation, Phys-
ioneal 35, has been developed. As some PD patients re-
quire a PD solution with a total buffer concentration of
35 mmol/L for optimal acid-base balance, Physioneal 35
was formulated to contain 25 mmol/L bicarbonate and
10 mmol/L lactate. This new formulation also contains
1.75 mmol/L calcium, rather than the 1.25 mmol/L con-
tent in Physioneal 40, since the need for low calcium PD
solutions has been reduced with the availability of non-
calcium phosphate binders. While Physioneal 35 has been
shown to be safe and efficacious and cause less pain on in-
fusion in clinical studies [9], no reports describing the bio-
compatibility profile of Physioneal 35 have yet appeared
in the scientific literature. Although this formulation is
similar to its parent formulation, the concentrations of
two important ions have been altered, thus requiring
the generation of biocompatibility data in order to avoid
the pitfall of a priori reasoning. This report establishes a
biocompatibility profile of this new bicarbonate/lactate-
buffered dialysis fluid formulation.
METHODS
Fluids
Physioneal 35 was compared with Physioneal 40 and
a conventional dialysis fluid in this study. Dianeal PD1
was used as the conventional dialysis fluid in all assays as
its calcium and buffer concentration corresponds to Phy-
sioneal 35. Five biocompatibility assays were performed
to establish the biocompatibility profile of Physioneal 35.
All PD solutions were provided by Baxter Healthcare
Corporation (Nivelles, Belgium); their formulations are
described in Table 1. The bicarbonate solutions were sup-
plied as a double chamber bag system. Immediately prior
to use a frangible seal separating the two chambers was
broken and the fluids mixed thoroughly.
Murine fibroblasts
Inhibition of cell growth was determined using a
murine fibroblast cell line L-929 as previously described
[8]. Briefly, murine fibroblasts were grown as adherent
cultures, counted, and seeded at 2000 cells per well in
96-well tissue culture plates. The cells were then allowed
Table 1. Composition of PD fluids used in this study
Physioneal Physioneal Conventional PD
35 40 fluid (Dianeal PD1)
Glucose % 1.36/3.86 1.36/3.86 1.36/3.86
Sodium mmol/L 132 132 132
Chloride mmol/L 101 95 102
Calcium mmol/L 1.75 1.25 1.75
Magnesium mmol/L 0.25 0.25 0.75
Lactate mmol/L 10 15 35
Bicarbonate mmol/L 25 25 —
pH at 25◦C 7.3 7.3 5.2
to attach for 24 hours before 72-hour exposure to Phy-
sioneal 35, Physioneal 40, or conventional dialysis fluid
pH neutralized with bicarbonate (25 mmol/L final HCO−3
concentration). All PD solutions were diluted 1:1 in mod-
ified Eagle’s medium. Fetal bovine serum was added to
a 10% final concentration. Each solution was added to
eight wells and measured in seven replicates (56 wells
total). Cell growth was assayed by the ability to take up
neutral red dye. Optical density (OD), which corresponds
to cell viability, was measured at 540 nm [10, 11].
Human neutrophils
Human neutrophils (PMN) were prepared from the
peripheral blood of six separate healthy volunteers by
dextran sedimentation and Ficoll-Paque (Amersham
Pharmacia Biotech AB, Uppsala, Sweden) density gradi-
ent centrifugation as described previously [12]. Following
Ficoll-Paque separation, the supernatant was removed
and the PMN pellet was resuspended and lysed to remove
unwanted red blood cells using 0.2% and 1.6% NaCl solu-
tion. The PMN were washed in phosphate-buffered saline
(PBS) before experimentation [13]. PMN (100 lL at a
concentration of 1 × 107 cells/mL) were incubated with
5 mL of each control and test solution for 15 minutes at
37◦C with continuous tube rotation. The cells were then
washed three times in 5 mL of PBS, recounted (in 1 mL
PBS), and resuspended to 1 × 106 cells/mL.
Following incubation with each control and test so-
lution, total ATP was extracted by adding 250 lL of
benzalkonium chloride extract (1 mg/mL) to 100 lL
of PMN (1 × 106 cells/mL) and subsequently 250 lL
of 25 mmol/L HEPES/10 mmol/L EDTA. Firefly biolumi-
nescence reagent (ATP Bioluminescence CLS reagent;
Roche Diagnostics, Mannheim, Germany, 25 lL) was
added to 25 lL of extracted sample and ATP content was
measured using a MLX microtiter plate luminometer
(Dynex Technologies, Inc., Chantilly, VA, USA). Under
the conditions used, there was a direct correlation be-
tween relative light units (RLU) and ATP concentration
[6, 14].
Following incubation with control and test solutions,
luminol-dependent chemiluminescence was measured
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using MLX microtiter plate luminometer (Dynex Tech-
nologies) at 37◦C. Samples for CL assay contained 50 lL
Krebs-Ringer phosphate buffer, 100 lL PMN (2 × 106
cells/mL), and 25 lL (10 lmol/L) luminol (5-amino-2,3-
dihydro-1,4-tetrazine-dione). All samples were preincu-
bated at 37◦C for six minutes prior to addition of a
target particle in order to achieve temperature equili-
bration and record background. The target particles were
added to the wells in a volume of 25 lL following dilution
to 1 lmol/L. Each sample was tested in quadruplicate. The
luminometer expressed the results as RLU [6].
Peritoneal mesothelial cells
Human peritoneal mesothelial cells (HPMC) were
isolated from omental tissue of five different donors un-
dergoing elective abdominal surgery. Isolation and char-
acterization of the HPMC was carried out as previously
described [15]. HPMC (at either passage level 1 or 2)
were used following growth arrest for 48 hours. HPMC
were seeded at a density of 2 × 104 cells/cm2 on 24-well
plates and allowed to become confluent. The cells were
exposed to 0.5 mL of test fluid (added to each well) in trip-
licate for 15 minutes. The cells were washed three times
with medium and interleukin 1b (IL-1b) (100 pg/mL) and
then stimulated with IL-1b for 24 hours at 37◦C. The su-
pernatants were centrifuged (13,000 RPM/g; 3 minutes)
and stored at –70◦C until IL-8 content was quantified
by enzyme-linked immunosorbent assay (ELISA) (R&D
Systems, Abbingdon, UK) [16].
Advanced glycation end product formation
Generation of human serum albumin (HSA)–
associated fluorescence, following incubation in PD flu-
ids, was determined as described previously [17, 18].
Briefly, peritoneal dialysis fluid pH was adjusted to 7.4
and incubated with HSA as a model protein. Aliquots
were incubated for 5 or 20 days in the dark at 37◦C. Albu-
min was isolated by ultrafiltration and fluorescence inten-
sity was measured (excitation 350 nm, emission 430 nm).
HSA concentration of the samples in ammonium acetate
buffer was measured using Bradford reagent (BioRad
Laboratories, Hercules, CA, USA) in a microplate assay.
Statistical analysis
For the murine fibroblast assay, the optical density of
eight wells for each of the seven replicates were averaged
prior to the statistical analysis. For all cell assays statistical
analysis was performed using the Mann-Whitney U test
(StatViewTM SD+ GRAPHICS, SAS Institute, Cary, NC,
USA) for nonparametric data. Data are represented as
the mean [± standard error of the mean (SEM)] of the
total number of individual experiments.
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Fig. 1. Murine fibroblast viability following exposure to dialysis fluid
(3.86% glucose) and assayed by the ability to take up neutral red dye.
The data are presented as mean optical density (± SEM) at 540 nm
for each test sample category. ∗P < 0.005 for conventional peritoneal
dialysis (PD) fluid compared with both Physioneal 35 and 40.
RESULTS
Murine fibroblast cell growth was most severely im-
paired by the conventional dialysis fluid tested following
72-hour exposure. Physioneal 35 and Physioneal 40 so-
lutions showed a statistically significant (P < 0.005) im-
provement in cell growth compared to conventional PD
fluid (OD at 540 nm; Physioneal 35, 0.416 ± 0.016 and
Physioneal 40, 0.376 ± 0.015 vs. conventional, 0.263 ±
0.013 SEM) (Fig. 1). The improvement in cell growth was
similar with Physioneal 35 and Physioneal 40.
Neutrophil viability, as measured by ATP content, fol-
lowing acute exposure to dialysis fluids was similar in Phy-
sioneal 35 and Physioneal 40 for 3.86% glucose (RLU;
Physioneal 35, 7.46 ± 1.39 vs. Physioneal 40, 6.21 ±
1.30) (Fig. 2A) and 1.36% glucose (RLU; Physioneal 35,
10.81 ± 1.30 vs. Physioneal 40, 7.93 ± 1.08). In contrast,
neutrophil viability was significantly improved (P < 0.05)
over acidic conventional PD fluid for both 3.86% and
1.36% glucose concentrations respectively (RLU; con-
ventional 3.86%, 3.49 ± 0.57 and conventional 1.36%,
3.53 ± 0.51). There were no significant differences in neu-
trophil viability between Physioneal formulations and
pH-neutralized conventional PD fluids at 3.86% glucose
(RLU; conventional pH 7.3, 4.90 ± 0.33) or 1.36% glu-
cose (RLU; conventional pH 7.3, 6.94 ± 0.97).
Neutrophil respiratory burst following 15-minute ex-
posure to dialysis fluids was similar in Physioneal 35 and
Physioneal 40 for 3.86% glucose (Physioneal 35, 84.19 ±
12.67 vs. Physioneal 40, 68.33 ± 8.87) (Fig. 2B) and for
1.36% glucose (Physioneal 35, 75.51 ± 12.61 vs. Phys-
ioneal 40, 89.78 ± 14.43, respectively). Respiratory burst
was significantly improved (P < 0.005) over conventional
PD fluid for both glucose concentrations (conventional
3.86%, 17.48 ± 8.69 and conventional 1.36%, 16.03 ±
6.57). When the pH of conventional PD fluid was adjusted
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Fig. 2. Neutrophil viability and chemilumi-
nescence following 15-minute exposure to
dialysis fluids (3.86% glucose). (A) Neu-
trophil viability presented as mean (± SEM)
relative light units (RLU). ∗∗P < 0.05 com-
pared with conventional dialysis fluid at pH
5.2. (B) Neutrophil chemiluminescence (CL)
response following stimulation with 1 lmol/L
phorbol 12-myristate 13-acetate (PMA) pre-
sented as mean (± SEM) RLU. ∗P < 0.005
compared with conventional dialysis fluid at
pH 5.2.
to a physiologic pH, the respiratory burst response was
similar to the Physioneal solutions and significantly better
(P < 0.05) than the conventional acidic lactate solution
(conventional 3.86% pH 7.3, 54.01 ± 13.64 and conven-
tional 1.36% pH 7.3, 53.31 ± 13.40), indicating that the
acute inhibition of respiratory burst caused by conven-
tional dialysis fluids is primarily dependent upon pH, as
reported previously [13].
IL-8 production was used as a measure of human peri-
toneal mesothelial cell function following acute exposure
to dialysis fluids and IL-1b stimulation (Fig. 3). There was
a trend toward improved IL-1b–stimulated IL-8 secre-
tion with Physioneal 35 and Physioneal 40 as compared
with the conventional PD solution, which did not reach
statistical significance (conventional, 1478 ± 409 pg/mL
vs. Physioneal 35, 2394 ± 365 pg/mL).
For each PD fluid, HSA-associated fluorescence, as a
measure of AGE formation, increased with increasing
incubation time and was greater with the higher glu-
cose concentration (Fig. 4). Rate of increase of fluores-
cence generation was greatest during the first five days
(0–5 days) for each PD fluid. Incubation of HSA in the
conventional PD fluids generated more AGE fluores-
cence than in either of the two compartment PD fluids
(Physioneal 40 and Physioneal 35) of equal glucose con-
centration after 5- and 20-day incubation at 37◦C. AGE
fluorescence generation in Physioneal 40 and Physioneal
35 was similar at both time points for equivalent glucose
concentrations.
DISCUSSION
The biocompatibility of a PD solution has become an
important element in its overall performance profile, as it
is believed to contribute to the sustainability of the peri-
toneal membrane. The new bicarbonate/lactate-buffered
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Fig. 3. Human peritoneal mesothelium cell
interleukin (IL)-8 production as measured by
sandwich enzyme-linked immunosorbent as-
say (ELISA) following 15 minutes’ exposure
to dialysis fluids (3.86% glucose) and then
stimulated with IL-1b for 24 hours. The data
are presented as pg/mL and are the mean
(± SEM).
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Fig. 4. Human serum albumin (HSA)-associated fluorescence. In-
crease in HSA-associated fluorescence following incubation with peri-
toneal dialysis (PD) fluids containing either 1.36% or 3.86% glucose.
Fluorescence is in arbitrary units per g (of HSA)/L.
PD solution studied in this report (Physioneal 35) is for-
mulated to provide efficient dialysis therapy for patients
requiring low buffer and high calcium content, while pro-
viding characteristics associated with a favorable biocom-
patibility profile. To test the in vitro biocompatibility of
Physioneal 35, a selection of assay systems and cell types
were employed to evaluate various physico-chemical pa-
rameters associated with biocompatibility.
General cytotoxicity, AGE formation, and acute cyto-
toxicity were evaluated for this biocompatibility assess-
ment. As many basic cellular mechanisms are similar in
both specialized and nonspecialized cells, cytotoxicity can
be qualitatively extrapolated from established cell lines
[19, 20]. Seventy-two–hour exposure of murine fibrob-
lasts to PD solutions provides a qualitative indication of
how cells may be affected upon chronic PD fluid expo-
sure. Several groups have now shown that the cytotoxic-
ity being measured by this assay system in conventional
dialysis solutions is mainly due to their GDP content
[8, 21]. The GDP content of any glucose-based solution
is thought to primarily cause damage to the peritoneal
membrane via the formation of AGE [22]. While the ex-
act mechanisms by which AGE formation in the peri-
toneal membrane affect its structure and function remain
unclear, strong evidence suggests that peritoneal perme-
ability, decreased ultrafiltration volume, and peritoneal
damage are related to the severity of peritoneal AGE ac-
cumulation [7, 23, 24]. Consequently, in vitro measure-
ment of advanced glycation of albumin is considered
a useful measure of biocompatibility performance and
was selected as a quantitative tool for this study. While
the GDP content and AGE formation appear to have a
detrimental effect on the peritoneal membrane following
prolonged exposure, rapidly changing physico-chemical
characteristics, such as the pH and pCO2 are also associ-
ated with cytotoxicity [6, 14]. Thus, PMN and HPMC were
acutely exposed to PD solutions. The cell types employed
and acute exposures to PD solutions are designed to more
closely mimic the initial minutes of a PD exchange before
the pH and pCO2 equilibrates to physiologic levels. The
combination of these commonly used assays provides an
overall assessment of biocompatibility of Physioneal 35.
All studies employed in this report demonstrated that
the biocompatibility profile of Physioneal 35 is equivalent
to that of Physioneal 40. Furthermore, biocompatibility
was significantly improved in most assays relative to con-
ventional PD solution. As shown in Figure 1, the growth
impairment in murine fibroblast cells incubated 72 hours
with Physioneal 35 was similar to Physioneal 40 and
significantly improved compared with conventional PD
fluid. As the pH of conventional PD fluid is neutralized in
this assay, the difference in fibroblast growth inhibition is
likely due to the lower concentration of cytotoxic glucose
degradation products in the Physioneal products. The
PMNs acutely exposed to PD solutions were functionally
similar in Physioneal 35 and Physioneal 40, and not sta-
tistically different from conventional PD fluid at pH 7.3
(Fig. 2). However, PMNs incubated with Physioneal 35
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displayed greater viability and a higher respiratory burst
compared with conventional PD fluid at its original pH.
IL-1b–stimulated mesothelial IL-8 production was not
statistically significantly improved in Physioneal 35 over
conventional PD fluid; however, the trend suggests that
subtle differences may exist. AGE formation with Phys-
ioneal 35 was similar to the Physioneal 40 formulation for
equivalent glucose concentrations, and greatly improved
over conventional lactate-buffered dialysis solutions. The
difference is likely related to their lower concentration of
GDPs, some of which are known to be highly reactive in-
termediates in AGE formation and hence responsible for
their accelerated generation [25].
CONCLUSION
Physioneal 35 is a new, neutral-pH, bicarbonate/
lactate-buffered PD solution for patients needing a PD
solution with a lower buffer and higher calcium content
than the available Physioneal 40 solution. Physioneal 35
displays an in vitro biocompatibility profile that is signif-
icantly better than its conventional acidic, lactate-based
solution counterpart. The pattern of reduced AGE for-
mation and cytotoxicity, along with the improved cell
function seen in this study, suggest that this generation
of more physiologic PD solutions may contribute to the
success of long-term PD therapy.
Reprint requests to Line M. Skoufos, Baxter Healthcare Corporation,
1620 Waukegan Road, MPGR-R2, McGaw Park, IL 60085.
Email: line skoufos@baxter.com
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